A Potential Treatment & Biomarkers for Long COVID (E26) ft Prof Nancy Klimas скачать в хорошем качестве

A Potential Treatment & Biomarkers for Long COVID (E26) ft Prof Nancy Klimas

Dr. Nancy Klimas discusses groundbreaking approaches to understanding and treating ME/CFS and Long COVID. She emphasizes the importance of a holistic view of the body, exploring issues like immune senescence, oxidative stress, and latent viral reactivations. Highlighting an innovative nebulized antioxidant-antiviral treatment, Dr. Klimas explains its potential to restore immune function and improve patients’ quality of life. She also underscores the critical need for further research into biomarkers, immune dysfunction, and vascular issues. Find out more at longcovidtheanswers.com This podcast is CERTIFED CONTINUED PROFESSIONAL DEVELOPMENT CPD/CME. Healthcare Professionals and can earn 0.5 MainPro+ Credits! Please register at https://longcovidtheanswers.com/cpd-r... and watch via the CPD/ CME dashboard area to claim your credits. Professor Nancy Klimas is interviewed about the mechanisms behind how a nebulised medication caused a remarkable recovery from symptoms of ME/CFS and Long COVID in a small group of individuals and her objective to gain the ability to extend this research into a larger population of people with the hope of finding a viable treatment for these diseases. REFERENCES 1 Gil A, Hoag GE, Salerno JP, Hornig M, Klimas N, Selin LK. Identification of CD8 T-cell dysfunction associated with symptoms in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and Long COVID and treatment with a nebulized antioxidant/anti-pathogen agent a restropective case series. 2 Long COVID the Answers Episode 6:“PEM, Long COVID & It’s Management featuring Professor Todd Davenport” 3 Appelman B, Charlton BT, Goulding RP, Kerkhoff TJ, Breedveld EA, Noort W, Offringa C, Bloemers FW, van Weeghel M, Schomakers BV, Coelho P., Wüst Rob.C Muscle abnormalities worsen after post-exertional malaise in long COVID. Nature communications. 2024 Jan 4;15(1):1-5 #longhauler #longcovid #monoclonalantibodies #longcovid #nancyklimas @nancyklimas ‪@NSU_INIM‬